Business Wire

AL-ADTRAN

13.6.2024 14:01:33 CEST | Business Wire | Press release

Share
Adtran sets new industry benchmarks with optical pumping cesium atomic clocks

Adtran today launched two new optical cesium atomic clocks that set new standards in network time synchronization: the OSA 3300 Super High-Performance (OSA 3300 SHP) and the OSA 3350 Super Enhanced Primary Reference Clock+ (OSA 3350 SePRC+). As part of Adtran’s Oscilloquartz portfolio of industry-first optical cesium clocks, the devices leverage unique, state-of-the-art optical pumping technology to meet evolving demands across applications from scientific research to critical PNT infrastructure. The OSA 3300 SHP offers exceptional stability and accuracy, making it a valuable tool for metrology institutes and scientific research facilities. In contrast, the OSA 3350 SePRC+ is specifically designed to enhance holdover capabilities for PNT services. It maintains 100 days of 100-nanosecond precision, providing continuous and accurate timing even in environments where GPS/GNSS is unavailable. This makes it a crucial component for ensuring the integrity of mission-critical networks and supporting vital infrastructure and defense operations with reliable backup timing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613778509/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s new optical pumping cesium clocks are a significant breakthrough for the networking industry. (Photo: Business Wire)

“Our two new optical cesium clocks represent a major breakthrough, offering substantial benefits to a wide variety of industries. Take the OSA 3350 SePRC+, for instance – it ensures 100-nanosecond accuracy over a span of more than three months. This level of precision and stability is critical for infrastructures relying on continuous PNT services, providing our customers with supreme reliability and robust protection against escalating cyber threats to GPS/GNSS,” said Gil Biran, GM of Oscilloquartz, Adtran. “In an era marked by rising global tensions and heightened risks of state-sponsored interference in satellite communications, our latest innovation has arrived at a pivotal moment. It will greatly enhance our capacity to address the demand for secure and reliable network timing around the world. Building on our 75-year legacy and unmatched expertise, the OSA 3350 SePRC+ exemplifies our commitment to excellence in assured PNT technology. As pioneers in the field, we continue to set new benchmarks, consistently improving standards to meet the dynamic needs of our customers and the broader market.”

The OSA 3300 SHP and OSA 3350 SePRC+ redefine the capabilities of PRCs and ePRCs, unlocking new possibilities in their respective domains. The OSA 3300 SHP, with its superior Allan Deviation (ADEV) performance – twice as accurate as the 3300 HP with the same 10-year lifespan – ensures exceptional stability and accuracy, making it an ideal choice for metrology institutes and scientific research facilities. Its advanced feature set enables these institutions to achieve new levels of precision in their timekeeping and calibration processes, directly driving advancements in scientific research and industrial applications. Meanwhile, the OSA 3350 SePRC+ is specifically designed to enhance holdover capabilities for PNT services. This high-end optical cesium clock, together with our Super ePRTC+ combiner can maintain 100 days of 100-nanosecond precision, far exceeding previous industry records, and ensuring continuous and accurate timing even in environments where GPS/GNSS are unavailable.

“Our OSA 3300 SHP provides unprecedented accuracy in timekeeping, maintaining nanosecond precision over extended periods. This level of enhanced accuracy and stability is crucial for scientific research and metrology, supporting high-precision experiments and the calibration of instruments to the highest standards. The 3300 SHP allows researchers to conduct groundbreaking experiments in fields like quantum mechanics and relativity, where extreme accuracy is paramount,” commented Patrick Berthoud, time and frequency chief scientist at Oscilloquartz, Adtran. “At Oscilloquartz, we’re dedicated to advancing time and frequency technology, leveraging our world-renowned Swiss expertise in this field. Our latest innovations demonstrate our commitment to delivering superior solutions that meet the evolving demands of our customers, driving progress in both scientific research and industrial applications.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613778509/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release

Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye